cvot tirzepatide π‘ New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What ACC 26: SURPASS-CVOT - Tirzepatide
Pay in 4 interest-free payments of $5.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Oct 23 - Oct 28










:max_bytes(150000):strip_icc():focal(742x196:744x198)/harvey-fierstein-122324-1-cc5047188eed46018a25b2702bc0deb7.jpg)

















